drugset
drugset / Trial / NCT03691454

Compare Neoadjuvant Chemotherapy of DOS Versus SOX in Locally Advanced Gastric Adenocarcinoma.

NCT03691454 ↗

Phase 2/3 Unknown 258 enrolled Peking University
RandomizedParallel-groupOpen-labelTreatment

Summary

This is a randomized, multicenter, controlled, adaptive phase II/III clinical study. The aim is to compare neoadjuvant chemotherapy of Docetaxel，Oxaliplatin combined with S-1(DOS) versus Oxaliplatin combined with S-1(SOX) in locally advanced gastric adenocarcinoma

Timeline

Start
2018-06-28
Primary completion
2022-06-30
Completion
2023-06-30

Drugs

EvaluationDrugModalityDoseRoute
Subject Docetaxel Small molecule 50 mg/m2 Intravenous
Comparator Oxaliplatin Small molecule 85 mg/m2 Intravenous
Comparator Oxaliplatin Small molecule 130 mg/m2 Intravenous
Subject S-1 Small molecule 40 mg —
Subject S-1 Small molecule 50 mg —
Subject S-1 Small molecule 60 mg —
Background Trastuzumab Monoclonal antibody 4 mg/kg —
Background Trastuzumab Monoclonal antibody 6 mg/kg —

Indications

gastric adenocarcinoma